Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2· 4 mg versus semaglutide 1· 0 mg (the dose approved for …

Background Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed
to investigate a new formulation of oral semaglutide at higher investigational doses versus …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Background There are currently limited data regarding the effect of semaglutide 2· 4 mg in
individuals with obesity and prediabetes in clinical trials. We aimed to assess the efficacy …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Background Semaglutide 2· 4 mg once weekly has been investigated for weight
management in global populations. Differences exist between Asian and non-Asian …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …